Effect of RTS,S/AS01


Journal

NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863

Informations de publication

Date de publication:
25 Oct 2024
Historique:
received: 08 05 2024
accepted: 19 09 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

RTS,S/AS01

Identifiants

pubmed: 39455625
doi: 10.1038/s41541-024-00977-y
pii: 10.1038/s41541-024-00977-y
doi:

Types de publication

Journal Article

Langues

eng

Pagination

200

Informations de copyright

© 2024. The Author(s).

Références

World Health Organization. WHO recommends groundbreaking malaria vaccine for children at risk. https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk .
Garçon, N. & Van Mechelen, M. Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Rev. Vaccines 10, 471–486 (2011).
doi: 10.1586/erv.11.29 pubmed: 21506645
Laurens, M. B.RTS,S/AS01 vaccine (Mosquirix
McCall, M. B. B., Kremsner, P. G. & Mordmüller, B. Correlating efficacy and immunogenicity in malaria vaccine trials. Semin Immunol. 39, 52–64 (2018).
doi: 10.1016/j.smim.2018.08.002 pubmed: 30219621
White, M. T. et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis 15, https://doi.org/10.1016/S1473-3099(15)00239-X (2015).
Ubillos, I. et al. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children. BMC Med 16, 197 (2018).
doi: 10.1186/s12916-018-1186-4 pubmed: 30376866 pmcid: 6208122
Dobaño, C. et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nat Commun.10, https://doi.org/10.1038/s41467-019-10195-z (2019).
RTS SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet.386, https://doi.org/10.1016/S0140-6736(15)60721-8 (2015).
Sanchez, L. et al. Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique. npj Vaccines 5, 1–16 (2020).
Sun, P. et al. Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ. J. Immunol. 171, 6961–6967 (2003).
doi: 10.4049/jimmunol.171.12.6961 pubmed: 14662904
Kester, K. E. et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337–346 (2009).
doi: 10.1086/600120 pubmed: 19569965
Lumsden, J. M. et al. Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 + T cells. PLoS One 2011;6, https://doi.org/10.1371/journal.pone.0020775 . (2011).
Barbosa, A. et al. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect. Immun. 77, 4502–4509 (2009).
doi: 10.1128/IAI.00442-09 pubmed: 19651872 pmcid: 2747951
Olotu A. et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01 E and protection against P falciparum clinical malaria. PLoS One. 6, https://doi.org/10.1371/journal.pone.0025786 (2011).
Ndungu, F. M. et al. A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E. PLoS One.7, https://doi.org/10.1371/journal.pone.0052870 (2012).
Moncunill, G. et al. Distinct helper t cell type 1 and 2 responses associated with malaria protection and risk in rts,s/as01e vaccinees. Clin. Infect. Dis. 65, 746–755 (2017).
doi: 10.1093/cid/cix429 pubmed: 28505356 pmcid: 5850568
Moris, P., Jongert E., van der Most R. G. Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine. Hum Vaccines Immunother.14, https://doi.org/10.1080/21645515.2017.1381809 (2018).
Agnandji, S. T. et al. Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in gabonese children vaccinated with RTS,S/AS01E and RTS,S/AS02D. PLoS One.6, https://doi.org/10.1371/journal.pone.0018559 (2011).
Moncunill, G. et al. RTS,S/AS01E malaria vaccine induces memory and polyfunctional T cell responses in a pediatric African phase iii trial. Front Immunol.8, https://doi.org/10.3389/fimmu.2017.01008 . (2017).
Pallikkuth, S. et al. A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses. Elife 9, 1–25 (2020).
doi: 10.7554/eLife.51889
Hill D. L. et al. Immune system development varies according to age, location, and anemia in African children. Sci. Transl. Med.12, https://doi.org/10.1126/scitranslmed.aaw9522 (2020).
Ansong, D. et al. T cell responses to the RTS,S/AS01e and RTS,S/AS02D malaria candidate vaccines administered according to different schedules to Ghanaian Children. PLoS One 6, 1–9 (2011).
doi: 10.1371/journal.pone.0018891
Horowitz, A. et al. Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine. J. Immunol. 188, 5054–5062 (2012).
doi: 10.4049/jimmunol.1102710 pubmed: 22504653
Darrah, P. A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med 13, 843–850 (2007).
doi: 10.1038/nm1592 pubmed: 17558415
Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: Implications for vaccine design. Nat. Rev. Immunol. 8, 247–258 (2008).
doi: 10.1038/nri2274 pubmed: 18323851
Le Gallou, S. et al. IL-2 Requirement for Human Plasma Cell Generation: Coupling Differentiation and Proliferation by Enhancing MAPK–ERK Signaling. J. Immunol. 189, 161–173 (2012).
doi: 10.4049/jimmunol.1200301 pubmed: 22634617
Litjens, N. H. R. et al. IL-2 producing memory CD4+ T lymphocytes are closely associated with the generation of IgG-secreting plasma cells. J. Immunol. 181, 3665–3673 (2008).
doi: 10.4049/jimmunol.181.5.3665 pubmed: 18714042
Hugosson, E. et al. Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunol. 26, 111–117 (2004).
doi: 10.1111/j.0141-9838.2004.00678.x pubmed: 15279621
Zhang, G. et al. Interleukin-10 (IL-10) polymorphisms are associated with IL-10: Production and clinical malaria in young children. Infect. Immun. 80, 2316–2322 (2012).
doi: 10.1128/IAI.00261-12 pubmed: 22566507 pmcid: 3416471
Swanson, B. J. et al. RANTES production by memory phenotype T cells is controlled by a posttranscriptional, TCR-dependent process. Immunity 17, 605–615 (2002).
doi: 10.1016/S1074-7613(02)00456-9 pubmed: 12433367
Conti, P. et al. Expression and secretion of RANTES by human peripheral blood CD4+ cells are dependent on the presence of monocytes. Ann. Clin. Lab Sci. 31, 75–84 (2001).
pubmed: 11314865
Frauenschuh, A. et al. Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine 23, 546–554 (2004).
doi: 10.1016/j.vaccine.2004.06.024 pubmed: 15530704
Obeng-Adjei, N. et al. Circulating Th1-Cell-type Tfh Cells that Exhibit Impaired B Cell Help Are Preferentially Activated during Acute Malaria in Children. Cell Rep. 13, 425–439 (2015).
doi: 10.1016/j.celrep.2015.09.004 pubmed: 26440897 pmcid: 4607674
The RTS,S Clinical Trials Partnership. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. N. Engl. J. Med. 367, 2284–2295 (2012).
The RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/ AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863–1875 (2011).
Sanz, H. et al. drLumi: An open-source package to manage data, calibrate, and conduct quality control of multiplex bead-based immunoassays data analysis. PLoS One 12, 1–18 (2017).
doi: 10.1371/journal.pone.0187901
Clement, F. et al. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Malar. J. 11, 1–15 (2012).
doi: 10.1186/1475-2875-11-384
Therneau, Terry M. Grambsch, P. M. Modeling Survival Data: Extending the Cox Model. Modeling Survival Data: Extending the Cox Model. 1–350 (New York, NY, 2000).

Auteurs

Robert A Mitchell (RA)

ISGlobal, Barcelona, Catalonia, Spain.
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.

Dídac Macià (D)

ISGlobal, Barcelona, Catalonia, Spain.
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.

Chenjerai Jairoce (C)

ISGlobal, Barcelona, Catalonia, Spain.
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Maxmillian Mpina (M)

Ifakara Health Institute. Bagamoyo Research and Training Centre, Bagamoyo, Tanzania.

Akshayata Naidu (A)

ISGlobal, Barcelona, Catalonia, Spain.

Ana Chopo-Pizarro (A)

ISGlobal, Barcelona, Catalonia, Spain.

Miquel Vázquez-Santiago (M)

ISGlobal, Barcelona, Catalonia, Spain.

Joseph J Campo (JJ)

ISGlobal, Barcelona, Catalonia, Spain.

Pedro Aide (P)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Ruth Aguilar (R)

ISGlobal, Barcelona, Catalonia, Spain.
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.

Claudia Daubenberger (C)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Carlota Dobaño (C)

ISGlobal, Barcelona, Catalonia, Spain. carlota.dobano@isglobal.org.
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain. carlota.dobano@isglobal.org.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain. carlota.dobano@isglobal.org.

Gemma Moncunill (G)

ISGlobal, Barcelona, Catalonia, Spain. gemma.moncunill@isglobal.org.
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain. gemma.moncunill@isglobal.org.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain. gemma.moncunill@isglobal.org.

Classifications MeSH